BioSpace News Archive

Clearside Biomedical, Inc. today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023.

Lyra Therapeutics, Inc. today announced completion of enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have had prior sinus surgery.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided financial guidance for 2023.

scPharmaceuticals Inc. announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.

Revolo Biotherapeutics today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, which is being held February 24-27 in San Antonio, Texas.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

PharmAla Biotech Holdings Inc. is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo MDMA and Engineering MDMA to Revive Therapeutics .

aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company) today announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).

cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an approach developed at Harvard, closes a $5.5 Million financing to get Series A-ready by the end of 2023.

Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced a collaboration to develop and enable use of New England Biolabs’ (NEB®) NEBNext® reagents and library preparation kits on Ultima sequencing platforms.